Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis
Sponsor: Shanghai Mabgeek Biotech.Co.Ltd
Summary
This study is a multicenter, randomized, double-blind, parallel controlled phase II study. It is planned to include approximately 60 subjects with moderate to severe atopic dermatitis(AD) to evaluate the efficacy and safety of MG-K10 monotherapy in adult patients with moderate to severe AD, and to observe PK characteristics, PD effects and immunogenicity.
Official title: A Phase II Clinical Study on the Efficacy and Safety of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Moderate to Severe Atopic Dermatitis
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-08-16
Completion Date
2027-12-16
Last Updated
2025-08-05
Healthy Volunteers
No
Conditions
Interventions
MG-K10 placebo
Administer the drug once every 4 weeks for a total of 6 times
Locations (2)
Tower 5,No.34,Chunxiao Road No.122 Pudong District, Shanghai, 201203.p R. china
Shanghai, Shanghai Municipality, China
Hangzhou First People's Hospital
Zhejiang, 杭州, China